Reata Pharma Files for Secondary Offering
Reata Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission for a secondary offering.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Reata Pharmaceuticals Inc. (NASDAQ: RETA) has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. The company did not disclose any pricing data, except that the offering is valued at roughly $86.25 million. The most recent closing price was $25.79 a share.
The underwriters for the offering are Citigroup, Cowen and Piper Jaffray.
This clinical stage biopharmaceutical company is focused on identifying, developing and commercializing product candidates to address rare and life-threatening diseases with few or no approved therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates, bardoxolone methyl and omaveloxolone, are members of a class of small molecules called antioxidant inflammation modulators and target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and inhibit pro-inflammatory signaling. Bardoxolone methyl is currently being studied in a Phase 3 trial, known as CATALYST, for the treatment of pulmonary arterial hypertension (PAH) associated with connective tissue disease, which began enrolling patients in October 2016.
[nativounit]
Bardoxolone methyl is also being studied in a Phase 2 trial known as LARIAT, for the treatment of pulmonary hypertension due to interstitial lung disease and PAH, each of which are subsets of pulmonary hypertension. In addition, the company recently met with the U.S. Food and Drug Administration (FDA) and received guidance on endpoints and general design for a single, pivotal Phase 2/3 trial utilizing bardoxolone methyl for the treatment of chronic kidney disease, caused by Alport syndrome. Omaveloxolone is being studied in Phase 2 trials for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma, known as MOXIe, MOTOR and REVEAL, respectively.
The company intends to use the net proceeds from the offering to further develop its pipeline, with the remainder going toward working capital and general corporate purposes.
Shares of Reata Pharma were last seen down 2.8% at $25.07, with a consensus analyst price target of $40.00 and a 52-week trading range of $11.03 to $41.60.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
